Coya Therapeutics (NASDAQ:COYA) Upgraded by Roth Mkm to “Strong-Buy” Rating

Coya Therapeutics (NASDAQ:COYA) was upgraded by research analysts at Roth Mkm to a “strong-buy” rating in a research report issued to clients and investors on Friday,Zacks.com reports.

Several other equities research analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Monday, April 20th. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Friday, April 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Price Performance

COYA opened at $4.42 on Friday. The company has a market capitalization of $103.69 million, a price-to-earnings ratio of -3.84 and a beta of 0.62. The firm’s fifty day moving average price is $4.45 and its two-hundred day moving average price is $4.90. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. The company had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. As a group, equities analysts anticipate that Coya Therapeutics will post -1.5 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. purchased a new stake in Coya Therapeutics in the fourth quarter worth $4,640,000. AWM Investment Company Inc. purchased a new stake in Coya Therapeutics in the fourth quarter worth $4,205,000. CM Management LLC lifted its stake in Coya Therapeutics by 16.7% in the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after acquiring an additional 50,000 shares during the period. Private Management Group Inc. purchased a new stake in Coya Therapeutics in the fourth quarter worth $1,626,000. Finally, Marshall Wace LLP lifted its stake in Coya Therapeutics by 438.8% in the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after acquiring an additional 183,533 shares during the period. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.